Five cardiac hormones decrease the number of human small-cell lung cancer cells

European Journal of Clinical Investigation

Volumn 35, Issue 6, 2005, Pages 388-398

  Vesely, B A ^a,c   Song, S ^b,c   Sanchez Ramos, J ^b,c   Fitz, S R ^a,c   Alli, A A ^a,c   Solivan, S M ^a,c   Gower Jr , W R ^a,b,c   Vesely, David L ^a,b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Biochemistry and Molecular Biology ^*  (United States)

Author keywords

Atrial natriuretic peptides; Cancer cell proliferation; Cyclic GMP; DNA synthesis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DNA; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ADENOCARCINOMA; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CARCINOMA, SMALL CELL; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PROTEIN PRECURSORS;

EID: 20444439224     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01501.x     Document Type: Article

References (41)

1. Gardner DG, Kovacic-Milivojevic BK, Garmai M. Molecular biology of the natriuretic peptides. In: Vesely DL, editor. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost; 1997.pp. 15-38.
2. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
3. Vesely DL. Natriuretic hormones. In: Alpern RJ Hebert SC, editors. The Kidney: Physiology and Pathophysiology, 4th edn. San Diego, CA: Elsevier/Academic Press; 2005.
4. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987;148:1540-8.
5. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-8.
6. 2. J Clin Invest 1992;89:1411-7.
7. Benjamin BA, Peterson TV. Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995;269:R1351-5.
8. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
9. Villarreal D, Reams GP, Taraben A, Freeman RH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999;221:166-70.
10. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001;280:R1510-7.
11. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-34.
12. Vesely DL, Douglass MA, Dietz JR, Gower WR, Jr, McCormick MT Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-40.
13. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-9.
14. Vesely DL. Atrial Natriuretic Hormones. Englewood Cliffs NJ: Prentice Hall; 1992.pp. 1-256.
15. Barr CS, Rhodes P, Struthers AD. C-type natriuretic peptide. Peptides 1996;17:1243-51.
16. Lainchbury J, Richards AM, Nicholls MG. Brain natriuretic peptide in heart failure. In: Vesely DL, editor. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost; 1997.pp. 151-8.
17. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-77.
18. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
19. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL, Epstein M. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989;192:230-5.
20. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 1998;58:205-16.
21. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000;58:374-8.
22. De Palo EF, Woloszczuk W, Meneghetti M, DePalo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000;46:843-7.
23. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001;59:1928-34.
24. Vesely BA, McAfee Q, Gower WR, Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
25. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR, Jr et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005;35:60-9.
26. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower WR, Jr. Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 2004;34:674-82.
27. Kelley MJ, Johnson BE. Molecular biology of lung cancer. In: Mendlesohn J, Howley PM, Israel MA et al., editors. The Molecular Basis of Cancer, 2nd edn. Philadelphia: W.B. Saunders Company;2001.pp. 260-87.
28. Fisher ER, Palekar A, Paulson JD. Comparative histopathologic, histochemical, electron microscopy and tissue culture studies of bronchial carcinoids and oat cell carcinomas of lung. Am J Clin Pathol 1978;69:165-72.
29. Gratzner HG. Monoclonal antibody to 5-bromo-ad 5-lododeoxyuridine: A new reagent for detection of DNA replication. Science 1982;218:474-5.
30. Yu CCW, Woods AL, Levison DA. The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J 1992;24:121-31.
31. Morstyn G, Pyke K, Gardner J, Ashcroft R, deFazio A, Bhathal P. Immunohistochemical identification of proliferatory cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J Histochem Cytochem 1986;34:697-701.
32. Qin Y, Williams G. Comparison of the classical autoradiographic and immunohistochemical methods with BrdU for measuring proliferation parameters in colon cancer. Anticancer Res 1993;13:731-6.
33. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984;259:14332-4.
34. Vesely DL. Signal transduction: Activation of the guanylate cyclase-cyclic guanosine-3′5′ monophosphate system by hormones and free radicals. Am J Med Sci 1997;314:311-23.
35. Ohaski Y, Yang HK, Le PT, Jensen RT, Johnson BE. Human small-cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res 1993;53:3165-71.
36. Rashed HM, Sun H, Patel TB. Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors. Hepatology 1993;17:677-84.
37. Lelievre V, Pineau N, Hu Z, Ioffe Y, Byun JY, Muller JM et al. Proliferative actions of natriuretic peptides on neuroblastoma cells. Involvement of guanylyl cyclase and non-guanylyl cyclase pathways. J Biol Chem 2001;276:43668-76.
38. Suga SI, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Ogawa Y et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992;130:229-39.
39. Murthy KS, Teng B, Jin J, Makhlouf GM. G-protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor. Am J Physiol 1998;275:C1409-16.
40. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
41. Vaporciyan AA, Kies M, Stevens C, Komaki R, Roth JA. Cancer of the lung. In: Kufe DW, Pollock RE, Weichselbaum RR et al., editors. Cancer Medicine, 6th edn. Hamilton, Ontario: BC Decker Inc;2003.pp. 1385-445.